Inventiva announced the publication in Clinical Gastroenterology and Hepatology of its analysis on new non-invasive biomarker signatures. These signatures are predictive of histological response following treatment with lanifibranor in patients with MASH and fibrosis.
The developed biomarker signatures for fibrosis improvement, MASH resolution, and composite histological endpoints demonstrated better predictive accuracy than existing diagnostic scores, including FIB4, FIBC3, ABC3D, NFS, ELF, and MACK-3. The signatures showed strong predictive accuracy, with AUROC values above 0.80, indicating high reliability in distinguishing responders from non-responders.
This analysis confirms that histological response to lanifibranor could be assessed using non-invasive signatures based on blood markers, potentially enabling physicians to identify patients most likely to benefit from treatment. The signatures were developed and validated using data from the Phase 2b NATIVE trial.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.